Quarterly report pursuant to Section 13 or 15(d)

BUSINESS (Details Narrative)

BUSINESS (Details Narrative)
9 Months Ended
Sep. 30, 2020
Jul. 28, 2016
BioCorRx Pharmaceuticals, Inc [Member] | BioCorRx, Inc [Member]    
Description of reverse stock split Effective January 22, 2019, the Company amended its Articles of Incorporation to implement a reverse stock split in the ratio of 1 share for every 100 shares of common stock. As a result, 259,984,655 shares of the Company’s common stock were exchanged for 2,599,847 shares of the Company’s common stock. These unaudited condensed consolidated financial statements have been retroactively restated to reflect the reverse stock split (See Note 15).  
Officer [Member] | BioCorRx Pharmaceuticals [Member]    
Equity issued ownership   75.80%
Non-Controlling Interest [Member]    
Equity issued ownership   24.20%